These are designated for use in cases of deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, particularly for locally advanced and/or metastatic conditions [56]. This evidence concerns the gene ERBB2 and breast cancer.